{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:21:19Z","timestamp":1792693279998,"version":"4.5.0"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic autoinflammatory disease of unknown origin, involving characterized by immune cell infiltration into the target tissue, central nervous system (CNS), resulting in local and\/or systemic inflammation. The symptoms vary from gait disturbance, visual impairment and learning and memory impairment and are being managed with corticosteroid and\/or immunosuppressive agents. However, several patients do not respond to these treatments, which can also elevate the risk of severe infections. Therefore, there remains an ongoing need to identify new therapeutic targets. MS exhibits distinctive pathology, clinical course, and treatment responses, suggesting the importance of targeting disease site-specific immune cells to mitigate immune system-induced inflammation, rather than employing broad immunosuppression. Chemokines and chemokine receptors play a crucial role in the pathogenesis of MS by recruiting immune cells to the CNS, leading to inflammation and demyelination. Therapies targeting chemokines have shown promising results in preclinical studies and clinical trials, but more research is needed to fully understand their mechanisms and optimize their efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1547256","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T07:50:40Z","timestamp":1742543440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Chemokines as therapeutic targets for multiple sclerosis: a spatial and chronological perspective"],"prefix":"10.3389","volume":"16","author":[{"given":"Nagisa Nakata","family":"Arimitsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Witkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Miyabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshishige","family":"Miyabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.4164","article-title":"Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis: the DOT-MS randomized clinical trial","volume":"82","author":"Coerver","year":"2025","journal-title":"JAMA Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7070078","article-title":"Multiple sclerosis: immunopathology and treatment update","volume":"7","author":"Dargahi","year":"2017","journal-title":"Brain Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13200","article-title":"Understanding the mechanisms that facilitate specificity, not redundancy, of chemokine-mediated leukocyte recruitment","volume":"160","author":"Dyer","year":"2020","journal-title":"Immunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nri722","article-title":"Chemokine receptors: multifaceted therapeutic targets","volume":"2","author":"Proudfoot","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01032-x","article-title":"New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine","volume":"20","author":"Xu","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70041-9","article-title":"Multiple sclerosis genetics","volume":"13","author":"Sawcer","year":"2014","journal-title":"Lancet Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1474-4422(15)00334-8","article-title":"The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets","volume":"15","author":"Hohlfeld","year":"2016","journal-title":"Lancet Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675307","article-title":"Cerebrospinal fluid findings in 541 patients with clinically isolated syndrome and multiple sclerosis: A monocentric study","volume":"12","author":"Berek","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ana.21748","article-title":"Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis","volume":"66","author":"Kebir","year":"2009","journal-title":"Ann Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070690","article-title":"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis","volume":"172","author":"Tzartos","year":"2008","journal-title":"Am J Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","author":"Frischer","year":"2009","journal-title":"Brain 132(Pt"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1191\/1352458503ms965oa","article-title":"Blood-brain barrier disruption in multiple sclerosis","volume":"9","author":"Minagar","year":"2003","journal-title":"Mult Scler"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/135245859900500206","article-title":"Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis","volume":"5","author":"Matusevicius","year":"1999","journal-title":"Mult Scler"},{"key":"B22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.21652","article-title":"T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta","volume":"65","author":"Durelli","year":"2009","journal-title":"Ann Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.566","article-title":"IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis","volume":"177","author":"Komiyama","year":"2006","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"15.1.1","DOI":"10.1002\/0471142735.im1501s77","article-title":"Experimental autoimmune encephalomyelitis in the mouse","volume":"15","author":"Miller","year":"2007","journal-title":"Curr Protoc Immunol Chapter"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902881","article-title":"Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis","volume":"184","author":"deLuca","year":"2010","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s0165-5728(99)00270-2","article-title":"Genetic and epigenetic influence on EAE phenotypes induced with different encephalitogenic peptides","volume":"108","author":"Sobel","year":"2000","journal-title":"J Neuroimmunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200146","article-title":"Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum","volume":"14","author":"Berek","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12974-019-1601-6","article-title":"Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases","volume":"16","author":"Lepennetier","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12974-016-0757-6","article-title":"Cytokine and chemokine alterations in tissue, CSF, and plasma in early presymptomatic phase of experimental allergic encephalomyelitis (EAE), in a rat model of multiple sclerosis","volume":"13","author":"Borjini","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5150","article-title":"Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients","volume":"103","author":"S\u00f8rensen","year":"1999","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149411","article-title":"B cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02695-z","article-title":"The presence of cerebellar B cell aggregates is associated with a specific chemokine profile in the cerebrospinal fluid in a mouse model of multiple sclerosis","volume":"20","author":"Schropp","year":"2023","journal-title":"J Neuroinflamm"},{"key":"B33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-018-1237-y","article-title":"An IFN\u03b3\/CXCL2 regulatory pathway determines lesion localization during EAE","volume":"15","author":"Stoolman","year":"2018","journal-title":"J Neuroinflamm"},{"key":"B34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12974-024-03247-9","article-title":"Impairment of spinal CSF flow precedes immune cell infiltration in an active EAE model","volume":"21","author":"Xin","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40478-019-0667-9","article-title":"Microglia pre-activation and neurodegeneration precipitate neuroinflammation without exacerbating tissue injury in experimental autoimmune encephalomyelitis","volume":"7","author":"Wimmer","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature08478","article-title":"Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions","volume":"462","author":"Bartholom\u00e4us","year":"2009","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/2045-8118-11-6","article-title":"Resolution of central nervous system astrocytic and endothelial sources of CCL2 gene expression during evolving neuroinflammation","volume":"11","author":"Shrestha","year":"2014","journal-title":"Fluids Barriers CNS"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-7-1","article-title":"Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide","volume":"7","author":"Chui","year":"2010","journal-title":"J Neuroinflamm"},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1084\/jem.20141015","article-title":"Neutrophil-related factors as biomarkers in EAE and MS","volume":"212","author":"Rumble","year":"2015","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(95)00008-p","article-title":"Chemokine expression in murine experimental allergic encephalomyelitis","volume":"58","author":"Godiska","year":"1995","journal-title":"J Neuroimmunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.12.7617","article-title":"CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis","volume":"166","author":"Fife","year":"2001","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/sj.jcbfm.9600055","article-title":"Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability","volume":"25","author":"Stamatovic","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400825","article-title":"Site-specific chemokine expression regulates central nervous system inflammation and determines clinical phenotype in autoimmune encephalomyelitis","volume":"193","author":"Stoolman","year":"2014","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.02.039","article-title":"Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis: IFN-\u03b3 and TNF-\u03b1 are important participants in the first attack but not in the relapse","volume":"340","author":"Hidaka","year":"2014","journal-title":"J Neurol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700155","article-title":"Expression of rat I-TAC\/CXCL11\/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands","volume":"84","author":"McColl","year":"2004","journal-title":"Lab Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.6.2525","article-title":"Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis","volume":"150","author":"Hulkower","year":"1993","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.immuni.2019.01.009","article-title":"Chemokine receptor redundancy and specificity are context dependent","volume":"50","author":"Dyer","year":"2019","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201605","article-title":"Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial","volume":"72","author":"Tak","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.33","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose","volume":"89","author":"Dairaghi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.967146","article-title":"Identification of potential drug targets for vascular dementia and carotid plaques by analyzing underlying molecular signatures shared by them","volume":"14","author":"Shu","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s0165-5728(03)00264-9","article-title":"Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease","volume":"142","author":"Eltayeb","year":"2003","journal-title":"J Neuroimmunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2405-14.2015","article-title":"CCR2 antagonism alters brain macrophage polarization and ameliorates cognitive dysfunction induced by traumatic brain injury","volume":"35","author":"Morganti","year":"2015","journal-title":"J Neurosci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63805-9","article-title":"Experimental autoimmune encephalomyelitis (EAE) in CCR2(-\/-) mice: susceptibility in multiple strains","volume":"162","author":"Gaupp","year":"2003","journal-title":"Am J Pathol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/s0165-5728(00)00274-5","article-title":"Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue","volume":"108","author":"Simpson","year":"2000","journal-title":"J Neuroimmunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.1c00373","article-title":"BMS-813160: A potent CCR2 and CCR5 dual antagonist selected as a clinical candidate","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2022.152245","article-title":"CCR1 antagonist J-113863 corrects the imbalance of pro- and anti-inflammatory cytokines in a SJL\/J mouse model of relapsing-remitting multiple sclerosis","volume":"227","author":"Ansari","year":"2022","journal-title":"Immunobiology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.757559","article-title":"Partial agonist and biased signaling properties of the synthetic enantiomers J113863\/UCB35625 at chemokine receptors CCR2 and CCR5","volume":"292","author":"Corbisier","year":"2017","journal-title":"J Biol Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/13550280600873819","article-title":"Anti-CCL2 treatment inhibits Theiler\u2019s murine encephalomyelitis virus-induced demyelinating disease","volume":"12","author":"Karpus","year":"2006","journal-title":"J Neurovirol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-013-0161-z","article-title":"Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases","volume":"36","author":"Bose","year":"2013","journal-title":"Arch Pharm Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy069","article-title":"T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention","volume":"141","author":"van Langelaar","year":"2018","journal-title":"Brain"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014043118","article-title":"Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2-expressing Treg cells","volume":"118","author":"Ronin","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.9.1874","article-title":"Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5","volume":"123","author":"Zang","year":"2000","journal-title":"Brain"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO;2-D","article-title":"Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent","volume":"30","author":"Rottman","year":"2000","journal-title":"Eur J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.6.713","article-title":"Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis","volume":"193","author":"Huang","year":"2001","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.013","article-title":"miR-23b suppresses leukocyte migration and pathogenesis of experimental autoimmune encephalomyelitis by targeting CCL7","volume":"26","author":"Zhang","year":"2018","journal-title":"Mol Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106314","article-title":"The role of chemokines and chemokine receptors in multiple sclerosis","volume":"83","author":"Cui","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-2-7","article-title":"Involvement of beta-chemokines in the development of inflammatory demyelination","volume":"2","author":"Banisor","year":"2005","journal-title":"J Neuroinflamm"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2009.01.014","article-title":"Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression","volume":"209","author":"Pigard","year":"2009","journal-title":"J Neuroimmunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112306","article-title":"The C-C chemokines CCL17 and CCL22 and their receptor CCR4 in CNS autoimmunity","volume":"18","author":"Scheu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2017.06.010","article-title":"Chemokine CCL17 is expressed by dendritic cells in the CNS during experimental autoimmune encephalomyelitis and promotes pathogenesis of disease","volume":"66","author":"Ruland","year":"2017","journal-title":"Brain Behav Immun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072321","article-title":"CCL18 exhibits a regulatory role through inhibition of receptor and glycosaminoglycan binding","volume":"8","author":"Krohn","year":"2013","journal-title":"PLoS One"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0800729","article-title":"CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells","volume":"183","author":"Kuwabara","year":"2009","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.11.088","article-title":"CCL20\/CCR6 chemokine signaling is not essential for pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis","volume":"641","author":"Sachi","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.11.006","article-title":"The combined effect of IL-17F and CCL20 gene polymorphism in susceptibility to multiple sclerosis in Egypt","volume":"685","author":"El Sharkawi","year":"2019","journal-title":"Gene"},{"key":"B75","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bbi.2013.04.011","article-title":"Dichotomy of CCL21 and CXCR3 in nerve injury-evoked and autoimmunity-evoked hyperalgesia","volume":"32","author":"Schmitz","year":"2013","journal-title":"Brain Behav Immun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-013-9775-z","article-title":"Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: a comparison between patients and healthy women","volume":"37","author":"Jafarzadeh","year":"2014","journal-title":"Inflammation"},{"key":"B77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1189\/jlb.0810442","article-title":"CCL22 regulates experimental autoimmune encephalomyelitis by controlling inflammatory macrophage accumulation and effector function","volume":"89","author":"Dogan","year":"2011","journal-title":"J Leukoc Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-18","article-title":"CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis","volume":"9","author":"Roy","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41467-021-22810-z","article-title":"Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms","volume":"12","author":"Shi","year":"2021","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2203-17.2018","article-title":"TRPM2 exacerbates central nervous system inflammation in experimental autoimmune encephalomyelitis by increasing production of CXCL2 chemokines","volume":"38","author":"Tsutsui","year":"2018","journal-title":"J Neurosci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41419-023-06126-y","article-title":"CXCR1 drives the pathogenesis of EAE and ARDS via boosting dendritic cells-dependent inflammation","volume":"14","author":"Zhuang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071605","article-title":"B cells in neuroinflammation: new perspectives and mechanistic insights","volume":"10","author":"Ahn","year":"2021","journal-title":"Cells"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2009.240","article-title":"Role of chemokines in CNS health and pathology: a focus on the CCL2\/CCR2 and CXCL8\/CXCR2 networks","volume":"30","author":"Semple","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-113","article-title":"Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"10","author":"Uzawa","year":"2010","journal-title":"BMC Neurol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134533","article-title":"Regulation of CNS precursor function by neuronal chemokines","volume":"715","author":"Watson","year":"2020","journal-title":"Neurosci Lett"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.550","article-title":"IFN-inducible protein 10\/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis","volume":"172","author":"Klein","year":"2004","journal-title":"J Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200206)32:6<1784::AID-IMMU1784>3.0.CO;2-R","article-title":"Neutralization of IFN-inducible protein 10\/CXCL10 exacerbates experimental autoimmune encephalomyelitis","volume":"32","author":"Narumi","year":"2002","journal-title":"Eur J Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-105","article-title":"Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model","volume":"11","author":"Mills Ko","year":"2014","journal-title":"J Neuroinflamm"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2008.00154.x","article-title":"Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis","volume":"18","author":"Kohler","year":"2008","journal-title":"Brain Pathol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1172\/JCI71951","article-title":"CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis","volume":"124","author":"Zohar","year":"2014","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.11.8053","article-title":"CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis","volume":"177","author":"McCandless","year":"2006","journal-title":"J Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/NIB-150101","article-title":"Targeting CXCL13 during neuroinflammation","volume":"6","author":"Huber","year":"2015","journal-title":"Adv Neuroimmune Biol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7676","article-title":"CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis","volume":"176","author":"Bagaeva","year":"2006","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.3.1620","article-title":"Critical roles of CXC chemokine ligand 16\/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis","volume":"173","author":"Fukumoto","year":"2004","journal-title":"J Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075021","article-title":"Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity","volume":"8","author":"Holm\u00f8y","year":"2013","journal-title":"PLoS One"},{"key":"B96","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4049\/jimmunol.1601329","article-title":"A novel \u03b19 integrin ligand, XCL1\/lymphotactin, is involved in the development of murine models of autoimmune diseases","volume":"199","author":"Matsumoto","year":"2017","journal-title":"J Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/480702","article-title":"Elevated expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the dorsal root ganglia and spinal cord in experimental autoimmune encephalomyelitis: implications in multiple sclerosis-induced neuropathic pain","volume":"2013","author":"Zhu","year":"2013","journal-title":"BioMed Res Int"},{"key":"B98","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1096\/fj.05-5465com","article-title":"The neuronal chemokine CX3CL1\/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system","volume":"20","author":"Huang","year":"2006","journal-title":"FASEB J"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2022.02.017","article-title":"CCR1 antagonist ameliorates experimental autoimmune encephalomyelitis by inhibition of Th9\/Th22-related markers in the brain and periphery","volume":"144","author":"Al-Mazroua","year":"2022","journal-title":"Mol Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.12.6873","article-title":"CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions","volume":"96","author":"Balashov","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B101","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1084\/jem.192.6.899","article-title":"CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis","volume":"192","author":"Fife","year":"2000","journal-title":"J Exp Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.12.1975","article-title":"Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges","volume":"58","author":"Trebst","year":"2001","journal-title":"Arch Neurol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.576967","article-title":"CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis","volume":"333","author":"Shou","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114153109","article-title":"CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells","volume":"109","author":"Poppensieker","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B105","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jneuroim.2011.04.008","article-title":"CCR4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function","volume":"236","author":"Forde","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.02.002","article-title":"The importance of CCR4 and CCR6 in experimental autoimmune encephalomyelitis","volume":"257","author":"Moriguchi","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8097","article-title":"CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL\/6 mice","volume":"7","author":"Gu","year":"2016","journal-title":"Oncotarget"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0713169","article-title":"Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response","volume":"182","author":"Liston","year":"2009","journal-title":"J Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2009.05.011","article-title":"Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis","volume":"213","author":"Elhofy","year":"2009","journal-title":"J Neuroimmunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/srep42856","article-title":"CCR7 deficient inflammatory Dendritic Cells are retained in the Central Nervous System","volume":"7","author":"Clarkson","year":"2017","journal-title":"Sci Rep"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.5.573","article-title":"Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice","volume":"193","author":"Chensue","year":"2001","journal-title":"J Exp Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63837-0","article-title":"CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages","volume":"162","author":"Trebst","year":"2003","journal-title":"Am J Pathol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12974-020-1730-y","article-title":"Neutrophil-selective deletion of Cxcr2 protects against CNS neurodegeneration in a mouse model of multiple sclerosis","volume":"17","author":"Khaw","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343499","article-title":"Th1-mediated experimental autoimmune encephalomyelitis is CXCR3 independent","volume":"43","author":"Lalor","year":"2013","journal-title":"Eur J Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01447-z","article-title":"NLRP3 exacerbates EAE severity through ROS-dependent NET formation in the mouse brain","volume":"22","author":"Byun","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jim.2009.09.007","article-title":"Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites","volume":"352","author":"Kim","year":"2010","journal-title":"J Immunol Methods"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905762116","article-title":"SerpinB1 controls encephalitogenic T helper cells in neuroinflammation","volume":"116","author":"Hou","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316510111","article-title":"Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis","volume":"111","author":"Ridderstad Wollberg","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235222","article-title":"CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis","volume":"14","author":"Moorman","year":"2023","journal-title":"Front Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202002465R","article-title":"ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases","volume":"35","author":"Pouzol","year":"2021","journal-title":"FASEB J"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.559583","article-title":"Inhibition of hyaluronan synthesis protects against central nervous system (CNS) autoimmunity and increases CXCL12 expression in the inflamed CNS","volume":"289","author":"Mueller","year":"2014","journal-title":"J Biol Chem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.03.013","article-title":"CXCL12 expression within the CNS contributes to the resistance against experimental autoimmune encephalomyelitis in Albino Oxford rats","volume":"216","author":"Miljkovi\u0107","year":"2011","journal-title":"Immunobiology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M001222200","article-title":"Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1","volume":"275","author":"Liang","year":"2000","journal-title":"J Biol Chem"},{"key":"B126","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/s0165-5728(02)00121-2","article-title":"Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES","volume":"128","author":"Matsui","year":"2002","journal-title":"J Neuroimmunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200200","article-title":"CXCL10\/IgG1 axis in multiple sclerosis as a potential predictive biomarker of disease activity","volume":"11","author":"Welsh","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.7.4091","article-title":"Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis","volume":"167","author":"Liu","year":"2001","journal-title":"J Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.819224","article-title":"CCR6 and CXCR6 identify the Th17 cells with cytotoxicity in experimental autoimmune encephalomyelitis","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94821","article-title":"Essential role for CCR6 in certain inflammatory diseases demonstrated using specific antagonist and knockin mice","volume":"2","author":"Robert","year":"2017","journal-title":"JCI Insight"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103001","article-title":"Concentration of evobrutinib, a BTK inhibitor, in cerebrospinal fluid during treatment of patients with relapsing multiple sclerosis in a phase 2 study","volume":"51","author":"Piasecka-Stryczynska","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131224","article-title":"Targeting CXCR7\/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system","volume":"211","author":"Williams","year":"2014","journal-title":"J Exp Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-170","article-title":"CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivo axial diffusivity","volume":"8","author":"Cruz-Orengo","year":"2011","journal-title":"J Neuroinflamm"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0695-9","article-title":"The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis","volume":"58","author":"Hermann","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1327672","article-title":"Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine","volume":"15","author":"Holm Hansen","year":"2024","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.msard.2019.06.016","article-title":"Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire","volume":"34","author":"Blumenfeld-Kan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B137","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-5728(00)00397-0","article-title":"Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta","volume":"112","author":"Zang","year":"2001","journal-title":"J Neuroimmunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-015-0068-1","article-title":"CXCL13 antibody for the treatment of autoimmune disorders","volume":"16","author":"Klimatcheva","year":"2015","journal-title":"BMC Immunol"},{"key":"B143","article-title":"Effect of methylprednisolone treatment on expression of sPECAM-1 and CXCL10 chemokine in serum of MS patients","volume":"58","author":"Micha\u0142owska-Wender","year":"2006","journal-title":"Pharmacol Rep"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S270872","article-title":"Targeting chemokines and chemokine receptors in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"13","author":"Dhaiban","year":"2020","journal-title":"J Inflammation Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509355068","article-title":"Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid","volume":"16","author":"Mellerg\u00e5rd","year":"2010","journal-title":"Mult Scler"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12565","article-title":"Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice","volume":"171","author":"Luo","year":"2014","journal-title":"Br J Pharmacol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1547256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T07:50:54Z","timestamp":1742543454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1547256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":147,"alternative-id":["10.3389\/fimmu.2025.1547256"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1547256","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1547256"}}